Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Generic Industry Consolidation Illustrated In ANDA Holder List

Dec 22 2016

• By Derrick Gingery

Related Content

Big paydays ahead as Actavis buys Allergan for $219/share

Nov 18 2014

GDUFA II: Facility Fees Might Be Deferred Until ANDA Approval

Jun 16 2015

Generic Drug User Fees Will Jump More Than 50% In FY 2018

Oct 17 2016

Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth

Jul 28 2016

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

GDUFA II: ANDAs, Not Facilities Will Govern Revenue

Sep 26 2016

ANDA Holder Fee Will Start With Industry-Driven Database 'Clean-Up'

Oct 23 2016

GDUFA II Will Include Small Business Relief, Priority ANDA Reviews

Aug 31 2016

Related Companies

Teva Pharmaceutical Industries Ltd.

Allergan plc

Allergan plc

Teva Pharmaceutical Industries Ltd.

Viatris Inc.

Novartis AG

Apotex Inc.

Additional Topics

United States Generic Drugs FDA Regulation BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window